BBT Biotech

Executive Summary

BBT Biotech GmbH is a privately held German biopharmaceutical company that specializes in the development, manufacturing, and global sales of biological active pharmaceutical ingredients (APIs). Founded in 2008 and headquartered in Berlin with GMP-certified facilities in Baesweiler near Aachen, the company's core capabilities include fermentation and protein purification technologies. Its primary focus is on producing viable bacteria, yeasts, and therapeutic proteins, notably thrombolytic drugs used to treat blood clots. While BBT Biotech operates in the high-demand biologics and antibodies space, it remains a relatively small player with limited public disclosures. The company has no disclosed pipeline or revenue figures, and its private status means financial details are unavailable. However, its expertise in GMP-compliant API manufacturing positions it as a potential contract development and manufacturing organization (CDMO) or supplier of niche biologics. Given the lack of transparency and absence of clinical-stage assets, the investment case is speculative and hinges on the company's ability to secure partnerships or expand its product offerings.

Upcoming Catalysts (preview)

• TBDPartnership or CDMO Agreement with Larger Pharma40% success
• TBDExpansion of Thrombolytic Drug API Capacity via New Facility30% success
• TBDRegulatory Approval for New Biological API Product in EU20% success